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The paper by S.N. Madhusudana et al.1 cannot be
left without comments. Potency (the amount of
antigen) in vaccine is one of the determinants of
immunogenicity and efficacy. In the case of tissue
culture rabies vaccines, this was recognized in the
early 1980s when 2.5 IU/dose was declared the
minimum acceptable level.2 This number was based
on administration of the vaccine as one full dose
intramuscularly. Reduced dose intradermal vaccine
schedules were not introduced until later that dec-
ade.3,4 We performed a study using Japanese-made
purified chick embryo vaccine (PCEC) with a potency
of 3.6 IU/ampoule, supplied with 1.0 mL diluent. It
had a much lower potency than found in current
German or Indian-made PCEC and French-made pur-
ified Vero cell vaccine (PVRV) batches which are
usually well above 6.0 IU per ampoule. The Japa-
nese PCEC resulted in an acceptable neutralizing
antibody response when used with the full 5-dose
intramuscular regimen and all patients bitten by
proven rabid dogs survived.5 However, we also
tested this batch using the intradermal schedule
and found that titers did not meet the World Health
Organization (WHO) criteria of all being above
0.5 IU/mL on day 14 of the series (P. Khawplod
and H. Wilde unpublished). We were disappointed,
as we had hoped to have found another approved
tissue culture vaccine that could be used in poor,
canine rabies endemic countries with the econom-
ical intradermal schedule. Our data were later con-
firmed by a Japanese investigator.6 D.J. Briggs and T.
Kamoltham had previously shown that Indian-made
PCEC (9.16 IU/vial) which, unlike PVRV (11.6 IU/
vial) was diluted in 1.0 ml rather than 0.5 mL, could
be used at 0.1 mL per intradermal dose and still
result in acceptable antibody titers.7,8 These studies
contradicted the WHO recommendation that PCEC
and other tissue culture vaccines diluted in 1.0 mL
rather than 0.5 mL, should be given as 0.2 mL per
intradermal dose. As a result of their work, the
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than 5.9 IU/ampoule, which was the potency of the
PCEC batch used by Kamoltham.8 We carried out
another unpublished study, using a PCEC batch with
a potency of 6.94 IU supplied with 1.0 mL diluent,
using the Thai Red Cross intradermal regimen and
equine rabies immune globulin on day 0. Neutraliz-
ing antibody titers were lower and several patients
had titers less than 0.5 IU/mL (the WHO minimal
acceptable level) on days 14 and 30.
Madhusudana’s study has serious defects in design
and execution. Antibody titers were determined
using the poorly reproducible mouse neutralization
test. There were no controls, such as a conventional
intramuscular regimen, that might have validated
the antibody titers. Results were reported as mean
and standard deviation and not as the conventional
geometric mean titer with range. The data would
have been more convincing if the conventional
rabies immune fluorescent focus inhibition test (RIF-
FIT) or even an ELISA had been used. Another defect
is the lack of an antibody determination on day 0
and 7. We have found in many similar studies that
almost every series of patients or volunteers had at
least one subject who initially denied having had a
prior rabies vaccine but was found to have neutra-
lizing antibody titers on day 0 and very high ones on
day 7, indicating an anamnestic response. When
questioning parents or grandparents, it was then
learned that subjects had been rabies vaccinated in
childhood. Even one such person among Madhusu-
dana’s volunteers would have distorted the data
significantly. Madhusudana apparently does not con-
sider vaccine potency important and we are not told
what it was. The authors only stated that the
potency of vaccine used was above the WHO mini-
mum level of 2.5 IU/vial. We have no objection to
the concept that PCEC batches of high potency (in
Thailand generally well above 5.0 IU) can be safely
used as 0.1 mL per intradermal dose with the WHO
approved standard (not modified) Thai Red Cross
regimen applied in Madhusudana’s study. We are
also sympathetic with Madhusudana’s motives in
carrying out this study in India, which is still usinges. Published by Elsevier Ltd. All rights reserved.
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derived Semple vaccine. He undoubtedly hoped it
would help to replace Semple vaccines with an
economical intradermal tissue culture regimen.
However, this study would have been more convin-
cing if he had followed an internationally accepta-
ble protocol and had a control group.
WHO is now in the process of compiling a new
Rabies Expert Committee Report (# 9). It is aware
that the reduced dose intradermal rabies vaccine
regimen is increasingly being used in developing
countries. We therefore suggest that the 2.5 IU
minimum vaccine potency recommendation by
WHO be amended to state that it applies only to
full dose intramuscular regimens. Local authorities
should be the ones to determine whether a vaccine
dose of 0.1 mL rather than 0.2 mL can be used safely
and effectively in their jurisdiction. Such a decision
must be based on confidence that vaccine potencies
in that area are considerably greater than 2.5 IU.
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